FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the reference product's label. Sandoz believes that the totality of evidence in its submission, including two pivotal clinical studies, will demonstrate that the proposed biosimilar is essentially the same as the reference product. Holzkirchen, October 2, 2015 - Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen's US-licensed Enbrel ^* (etanercept) - a tumor necrosis factor alpha (TNF-alpha) inhibitor. Sandoz is seeking approval for all indications included in the label of the reference product  which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis affecting approx. 1.3 million and 7.5 million people (respectively) in the US. Mark McCamish, M.D. Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz said "anti-TNFs will continue to play a leading role in immunology treatment and the acceptance of our regulatory submission by the FDA today is a significant step towards increasing patient access to these life-changing medicines." McCamish continued "we believe we are the first company to receive FDA file acceptance of a biosimilar version of etanercept." This is the second BLA submission by Sandoz using the 351(k) biosimilar pathway.